Diversity through phosphine catalysis identifies octahydro-1,6- naphthyridin-4-ones as activators of endothelium-driven immunity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 17, 2011, Pages 6769-6774

  Cruz, Daniel ^a   Wang, Zhiming ^b,c   Kibbie, Jon ^a   Modlin, Robert ^b   Kwon, Ohyun ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHANGZHOU UNIVERSITY   (China)

Author keywords

Immune activator; Medicinal chemistry; Nucleophilic phosphine catalyzed annulations; Solid phase library synthesis; Structure activity relationship analysis

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NAPHTHYRIDINE DERIVATIVE; OCTAHYDRO 1,6 NAPHTHYRIDIN 4 ONE DERIVATIVE; PHOSPHINE; UNCLASSIFIED DRUG;

ANNULATION REACTION; ARTICLE; CATALYSIS; CHEMICAL REACTION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DIELS ALDER REACTION; DRUG SCREENING; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYDROLYSIS; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MONOCYTE; PRIORITY JOURNAL; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION; TEBBE REACTION;

CATALYSIS; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MOLECULAR STRUCTURE; PHOSPHINES; STRUCTURE-ACTIVITY RELATIONSHIP;

ALNUS;

EID: 79955568049     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1015254108     Document Type: Article

References (52)

1. Schreiber SL, Kapoor TM, Wess G (2008) Chemical Biology: From Small Molecules to Systems Biology and Drug Design (Wiley-VCH, Weinheim, Germany).
2. Schreiber SL (2000) Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287:1964-1969.
3. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727-730. (Pubitemid 37361545)
4. Strausberg RL, Schreiber SL (2003) From knowing to controlling: A path from genomics to drugs using small molecule probes. Science 300:294-295. (Pubitemid 36433713)
5. Dolle RE, et al. (2010) Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2009. J Comb Chem 12:765-806.
6. Terret NK (1998) Combinatorial Chemistry (Oxford Univ Press, Oxford, UK).
7. Burke MD, Schreiber SL (2004) A planning strategy for diversity-oriented synthesis. Angew Chem Int Edit 43:46-58. (Pubitemid 38063470)
8. Nielsen TE, Schreiber SL (2008) Towards the optimal screening collection: A synthesis strategy. Angew Chem Int Edit 47:48-56.
9. Spandl RJ, Bender A, Spring DR (2008) Diversity-oriented synthesis; a spectrum of approaches and results. Org Biomol Chem 6:1149-1158. (Pubitemid 351432832)
10. Galloway WRJD, Isidro-Llobet A, Spring DR (2010) Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nat Commun 1:80-92.
11. Zhu XF, Lan J, Kwon O (2003) An expedient phosphine-catalyzed [4 + 2] annulation: Synthesis of highly functionalized tetrahydropyridines. J AmChem Soc 125:4716-4717. (Pubitemid 36505358)
12. Lu K, Kwon O (2009) Phosphine-catalyzed [4 + 2] annulation: Synthesis of ethyl 6-phenyl-1-tosyl-1,2,5,6-tetrahydropyridine-3-carboxylate. Org Synth 2009:212-224.
13. Xu Z, Lu X (1998) A novel [3 + 2] cycloaddition approach to nitrogen heterocycles via phosphine-catalyzed reactions of 2,3-butadienoates or 2-butynoates and dimethyl acetylenedicarboxylates with imines: A convenient synthesis of pentabromopseudilin. J Org Chem 63:5031-5041. (Pubitemid 128491707)
14. Zhu X, Henry CE, Kwon O (2005) A highly diastereoselective synthesis of 3-carbethoxy- 2,5-disubstituted-3-pyrrolines by phosphine catalysis. Tetrahedron 61:6276-6282. (Pubitemid 40812982)
15. Zhu XF, Henry CE, Wang J, Dudding T, Kwon O (2005) Phosphine-catalyzed synthesis of 1,3-dioxan-4-ylidenes. Org Lett 7:1387-1390. (Pubitemid 40544125)
16. Zhu XF, Schaffner AP, Li RC, Kwon O (2005) Phosphine-catalyzed synthesis of 6-substituted 2-pyrones: Manifestation of E/Z-isomerism in the zwitterionic intermediate. Org Lett 7:2977-2980. (Pubitemid 40992611)
17. Creech GS, Kwon O (2008) Alcohol-assisted phosphine catalysis: One-step syntheses of dihydropyrones from aldehydes and allenoates. Org Lett 10:429-432.
18. Creech GS, Zhu X, Fonovic B, Dudding T, Kwon O (2008) Theory-guided design of bronsted acid-assisted phosphine catalysis: Synthesis of dihydropyrones from aldehydes and allenoates. Tetrahedron 64:6935-6942.
19. Guo H, Xu Q, Kwon O (2009) Phosphine-promoted [3 + 3] annulations of aziridines with allenoates: Facile entry into highly functionalized tetrahydropyridines. J Am Chem Soc 131:6318-6319.
20. Tran YS, Kwon O (2007) Phosphine-catalyzed [4 + 2] annulation: Synthesis of cyclohexenes. J Am Chem Soc 129:12632-12633. (Pubitemid 350004451)
21. Sriramurthy V, Barcan GA, Kwon O (2007) Bisphosphine-catalyzed mixed double-Michael reactions: Asymmetric synthesis of oxazolidines, thiazolidines, and pyrrolidines. J Am Chem Soc 129:12928-12929. (Pubitemid 350058321)
22. Sriramurthy V, Kwon O (2010) Diphosphine-catalyzed mixed double-Michael reaction: A unified synthesis of indolines, dihydropyrrolopyridines, benzimidazolines, tetrahydroquinolines, tetrahydroisoquinolines, dihydrobenzo-1,4-oxazines, and dihydrobenzo- 3,1-oxazines. Org Lett 12:1084-1087.
23. Watanabe M, et al. (2008) Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 283:9571-9579.
24. Wang Z, et al. (2011) Diversity through a branched reaction pathway: Generation of multicyclic scaffolds and identification of antimigratory agents. Chem-Eur J 17:649-654.
25. Castellano S, et al. (2007) Small-molecule inhibitors of protein geranylgeranyltransferase type I. J Am Chem Soc 129:5843-5845. (Pubitemid 46748488)
26. Lu J, et al. (2009) In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase I. Mol Cancer Ther 8:1218-1226.
27. Butcher EC, Berg EL, Kunkel EJ (2004) Systems biology in drug discovery. Nat Biotechnol 22:1253-1259.
28. Berg EL, Kunkel EJ, Hytopoulos E, Plavec I (2006) Characterization of compound mechanisms and secondary activities by BioMAP analysis. J Pharmacol Toxicol 53:67-74.
29. Nakamoto T, Inagawa H, Takagi K, Soma G (2000) A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res 20:4087-4096.
30. Sorensen EW, Gerber SA, Frelinger JG, Lord EM (2010) IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol 184:1858-1866.
31. Miller CH, Maher SG, Young HA (2009) Clinical use of interferon-gamma. Ann NYAcad Sci 1182:69-79.
32. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M (2010) Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 7:284-289.
33. Rice JW, Davis JE, Crowl RM, Johnston PA (1996) Development of a high volume screen to identify inhibitors of endothelial cell activation. Anal Biochem 241:254-259. (Pubitemid 26346790)
34. Zerwes HG, Peter JC, Link M, Gubler H, Scheel G (2002) A multiparameter screening assay to assess the cytokine-induced expression of endothelial cell adhesion molecules. Anal Biochem 304:166-173. (Pubitemid 34522959)
35. Ren DC, Du GH, Zhang JT (2003) High throughput screening for intercellular adhesion molecule-1 inhibitor. Yao Xue Xue Bao 38:405-408.
36. May MJ, Wheeler-Jones CP, Pearson JD (1996) Effects of protein tyrosine kinase inhibitors on cytokine-induced adhesion molecule expression by human umbilical vein endothelial cells. Br J Pharmacol 118:1761-1771. (Pubitemid 26252672)
37. Pandey MK, et al. (2010) Design, synthesis and anti-inflammatory evaluation of PEGylated 4-methyl and 4,8-dimethylcoumarins. Eur J Pharm Sci 39:134-140.
38. Vergeer M, Stroes ES (2009) The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol 104:32E-38E.
39. Barter PJ, et al. (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122. (Pubitemid 350146106)
40. Metcalfe C, Wheeler BW, Gunnell D, Martin RM (2010) International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction. Pharmacoepidem Dr S 19:778-785.
41. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471. (Pubitemid 46919772)
42. Lukacs NW, et al. (1994) Intercellular adhesion molecule-1 mediates the expression of monocyte-derived MIP-1 alpha during monocyte-endothelial cell interactions. Blood 83:1174-1178.
43. Ball CP, et al. (1998) Chameleon catches in combinatorial chemistry: Tebbe olefination of polymer supported esters and the synthesis of amines, cyclohexanones, enones, methyl ketones and thiazoles. Chem Commun 2019-2020. (Pubitemid 128675898)
44. Barrett AMG, Procopiou PA, Voigtmann U (2001) Solid-phase synthesis of isoxazoles using vinyl ethers as chameleon catches. Org Lett 3:3165-3168. (Pubitemid 33621139)
45. Fukuyama T, Cheung M, Kan T (1999) N-carboalkoxy-2- nitrobenzenesulfonamides: A practical preparation of n-Boc, N-Alloc, and N-Cbz-protected primary amines. Synlett 1301-1303.
46. Zhou Y, et al. (2008) Library synthesis using 5,6,7,8-tetrahydro-1,6- naphthyridinesas scaffolds. J Comb Chem 10:534-540.
47. Eriksson EE, Xie X,Werr J, Thoren P, Lindbom L (2001) Direct viewing of atherosclerosis in vivo: Plaque invasion by leukocytes is initiated by the endothelial selectins. FASEB J 15:1149-1157. (Pubitemid 32436300)
48. Rossi B, Constantin G (2008) Anti-selectin therapy for the treatment of inflammatory diseases. Inflamm Allergy Drug Targets 7:85-93.
49. Laffer CL, Elijovich F (2010) Inflammation and therapy for hypertension. Curr Hypertens Rep 12:233-242.
50. Short KR, Blackett PR, GardnerAW, Copeland KC (2009) Vascular health in children and adolescents: Effects of obesity and diabetes. Vasc Health Risk Manag 5:973-990.
51. Cocchi F, et al. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811-1815.
52. Nakashima E, et al. (1996) A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm Res 13:1896-1901. (Pubitemid 27034126)